Patents by Inventor Anastasia Khvorova

Anastasia Khvorova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
    Patent number: 11702659
    Abstract: This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: July 18, 2023
    Assignees: UNIVERSITY OF MASSACHUSETTS, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Anastasia Khvorova, Vignesh Narayan Hariharan, Sarah Davis, Annabelle Biscans, Ananth Karumanchi
  • OLIGONUCLEOTIDES FOR SOD1 MODULATION
    Publication number: 20230193281
    Abstract: This disclosure relates to novel SOD1 targeting sequences. Novel SOD1 targeting oligonucleotides for the treatment of SOD1-related familial amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: November 8, 2022
    Publication date: June 22, 2023
    Inventors: Anastasia Khvorova, James W. Gilbert, Chantal Ferguson, Robert Brown, Alexandra Weiss
  • MODIFIED GUIDE RNAS FOR NEISSERIA MENINGITIDIS CAS9
    Publication number: 20230183687
    Abstract: Chemically modified Neisseria meningitidis (Nme) crRNAs, tracrRNAs, and sgRNAs are provided. Methods of using the Nme crRNAs, tracrRNAs, and sgRNAs for genome editing with a Nme CRISPR nuclease and kits for performing the same are also provided.
    Type: Application
    Filed: October 12, 2022
    Publication date: June 15, 2023
    Inventors: Erik Joseph Sontheimer, Jonathan Kenneth Watts, Anastasia Khvorova, Nathan Bamidele
  • RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
    Patent number: 11667915
    Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: June 6, 2023
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Tod M. Woolf, Joanne Kamens, William Salomon, Anastasia Khvorova
  • OPTIMIZED ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS
    Publication number: 20230078622
    Abstract: This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
    Type: Application
    Filed: June 22, 2022
    Publication date: March 16, 2023
    Inventors: Anastasia Khvorova, Vignesh Narayan Hariharan, Sarah Davis, Annabelle Biscans, Ananth Karumanchi
  • UNIVERSAL DYNAMIC PHARMACOKINETIC-MODIFYING ANCHORS
    Publication number: 20230061751
    Abstract: Therapeutic oligonucleotides comprising universal pharmacokinetic (PK)-modifying anchors are provided. Methods for treating diseases or disorders comprising administering to a subject a therapeutic oligonucleotide comprising one or more universal PK-modifying anchors are provided.
    Type: Application
    Filed: January 15, 2021
    Publication date: March 2, 2023
    Inventors: Anastasia Khvorova, Bruno Miguel da Cruz Godinho, Matthew Hassler
  • RNA interference in ocular indications
    Patent number: 11584933
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: February 21, 2023
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • OLIGONUCLEOTIDES FOR SARS-CoV-2 MODULATION
    Publication number: 20230021431
    Abstract: This disclosure relates to novel SARS-CoV-2 targeting sequences. Novel SARS-CoV-2 targeting oligonucleotides for the treatment of SARS-CoV-2 infection are also provided.
    Type: Application
    Filed: May 28, 2021
    Publication date: January 26, 2023
    Inventors: Anastasia Khvorova, Jonathan Watts, Zachary Kennedy, Annabelle Biscans, Bruno Miguel da Cruz Godinho, Chantal Ferguson, Dimas Echeverria Moreno, Ken Yamada, Daniel O'Reilly, Kathryn Monopoli, Vignesh Narayan Hariharan, Qi Tang, Sarah Davis, Samuel Hildebrand, Socheata Ly, Minwook Shin, Pranathi Meda Krishnamurthy, Nicholas McHugh, Jacquelyn Sousa, Jillian Caiazzi, Yann Thillier, Gitali Devi
  • DYNAMIC PHARMACOKINETIC-MODIFYING ANCHORS
    Publication number: 20220372476
    Abstract: Therapeutic oligonucleotides comprising pharmacokinetic (PK)-modifying anchors are provided. Methods for treating diseases or disorders comprising administering to a subject a therapeutic oligonucleotide comprising one or more PK-modifying anchors are provided.
    Type: Application
    Filed: April 20, 2022
    Publication date: November 24, 2022
    Inventors: Anastasia Khvorova, Bruno Miguel da Cruz Godinho, Matthew Hassler
  • Exosomal loading using hydrophobically modified oligonucleotides
    Patent number: 11505807
    Abstract: In one aspect, the invention relates to a method of loading exosomes with oligonucleotide cargo, by incubating an oligonucleotide comprising one or more hydrophobic modifications with a population of exosomes for a period of time sufficient to allow loading of the exosomes with the oligonucleotide. Exosomes loaded with hydrophobically modified oligonucleotide cargo, and uses thereof, are also provided.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: November 22, 2022
    Assignee: University of Massachusetts
    Inventors: Anastasia Khvorova, Neil Aronin, Marie Cecile Didiot, Reka Haraszti
  • OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS
    Publication number: 20220364100
    Abstract: This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
    Type: Application
    Filed: April 12, 2022
    Publication date: November 17, 2022
    Inventors: Anastasia Khvorova, Melissa Moore, Anton A. Turanov, Ananth Karumanchi
  • Dynamic pharmacokinetic-modifying anchors
    Patent number: 11492619
    Abstract: Therapeutic oligonucleotides comprising pharmacokinetic (PK)-modifying anchors are provided. Methods for treating diseases or disorders comprising administering to a subject a therapeutic oligonucleotide comprising one or more PK-modifying anchors are provided.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: November 8, 2022
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Bruno Miguel Da Cruz Godinho, Matthew Hassler
  • OLIGONUCLEOTIDES FOR SYNGR-3 MODULATION
    Publication number: 20220348918
    Abstract: This disclosure relates to novel SYNGR-3 targeting sequences. Novel SYNGR-3 targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
    Type: Application
    Filed: March 25, 2022
    Publication date: November 3, 2022
    Inventors: Anastasia Khvorova, Chantal Ferguson
  • TARGETING RLIM TO MODULATE BODY WEIGHT AND OBESITY
    Publication number: 20220340903
    Abstract: Methods for the treatment of weight-related disorders, including obesity and disorders associated with obesity, as well as underweight and disorders associated with underweight, by modulating Rlim levels.
    Type: Application
    Filed: September 25, 2020
    Publication date: October 27, 2022
    Inventors: Ingolf Bach, Feng Wang, Anastasia Khvorova, Chantal Ferguson
  • Methods and Compositions for Selecting siRNA of Improved Functionality
    Publication number: 20220315922
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.
    Type: Application
    Filed: November 5, 2021
    Publication date: October 6, 2022
    Applicant: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN MRNA
    Publication number: 20220251554
    Abstract: This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.
    Type: Application
    Filed: November 29, 2021
    Publication date: August 11, 2022
    Inventors: Anastasia Khvorova, Neil Aronin, Julia Alterman
  • O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES
    Publication number: 20220251555
    Abstract: Novel oligonucleotides that are fully chemically stabilized are provided. Methods of using oligonucleotides that are fully chemically stabilized are also provided.
    Type: Application
    Filed: January 20, 2022
    Publication date: August 11, 2022
    Inventors: Anastasia Khvorova, Julia Alterman, Sarah Davis, Anton Turanov
  • Neutral nanotransporters
    Patent number: 11396654
    Abstract: Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: July 26, 2022
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Michelle Miller, Karen G. Bulock
  • OLIGONUCLEOTIDES FOR DGAT2 MODULATION
    Publication number: 20220228141
    Abstract: This disclosure relates to novel DGAT2 targeting sequences. Novel DGAT2 targeting oligonucleotides for the treatment of non-alcoholic fatty liver disease (NAFLD) and lipodystrophy syndromes (or metabolic syndrome) are also provided.
    Type: Application
    Filed: November 22, 2021
    Publication date: July 21, 2022
    Inventors: Michael P. Czech, Batuhan Orbay Yenilmez, Anastasia Khvorova
  • AIM2 INHIBITORS AND USES THEREOF
    Publication number: 20220175816
    Abstract: Described herein are AIM2 inhibitors (e.g., inhibitory nucleic acids), vectors, cells (e.g., dendritic cells), and compositions comprising same, and methods of using same in the treatment of cancer (e.g., melanoma).
    Type: Application
    Filed: April 16, 2020
    Publication date: June 9, 2022
    Inventors: Keitaro Fukuda, John E. Harris, Anastasia Khvorova, Kate Fitzgerald